Stellantis Updates 2024 Financial Guidance
Stellantis Updates 2024 Financial Guidance AMSTERDAM, September 30, 2024 – Stellantis N.V. today revised its 2024 financial guidance, reflecting decisions […]
Mesoblast Option to Issue Up to US$50 Million Convertible Notes for Product Launch
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory […]
Dr. Robert Langer, Co-Founder of Moderna, Joins Scientific Advisory Board of Klotho Neurosciences, Inc. (KLTO)
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) — Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing […]
NIO Announces RMB3.3 Billion Investment in NIO China from Strategic Investors
SHANGHAI, Sept. 29, 2024 (GLOBE NEWSWIRE) — NIO Inc. (NYSE: NIO; HKEX: 9866; SGX: NIO) (“NIO” or the “Company”), a […]
Digicann Ventures Signs Definitive Agreement for Proposed RTO Transaction with 3Win Corp.
/ Not for distribution to U.S. news wire services or for dissemination in the United States / VANCOUVER, British Columbia, […]
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia
Updated Phase 1 data presented at ESH-iCMLf 26thAnnual John Goldman Conference Reported cumulative MMR rate of 44% (8/18) by 24 […]
Global Uranium Corp. Announces Change to Executive Management
VANCOUVER, British Columbia, Sept. 27, 2024 (GLOBE NEWSWIRE) — Global Uranium Corp. (CSE: GURN | OTC PINK: GURFF | FRA: […]
HYTN Files Business Acquisition Report
VANCOUVER, British Columbia, Sept. 27, 2024 (GLOBE NEWSWIRE) — HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” […]
Natural Alternatives International, Inc. Announces Fiscal 2024 Q4 and YTD Results
CARLSBAD, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and […]
BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events
– Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month […]
